ReviewFrontiers in immunology2025
γδ T cells in diabetes mellitus: dual roles and therapeutic implications.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic-epigenetic crosstalk in latent autoimmune diabetes in adults: potential roles of lactate-induced histone lactylation in immune regulation and pancreatic β-cell fate.Frontiers in endocrinology · 2026Review
- γδ T-cell interferon-γ production reflects metabolic improvement during SGLT2 inhibitor-based therapy in type 2 diabetes.Frontiers in endocrinology · 2026Article
- Material-driven glucose responsiveness in insulin delivery systems: carrier selection and performance.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is primarily categorized into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), which exhibit distinct pathogenic mechanisms. T1DM is characterized by an absolute deficiency of insulin secretion, predominantly resulting from the autoimmune-mediated destruction of pancreatic beta cells. In contrast, T2DM arises from a combination of insulin resistance in peripheral tissues and a compensatory insulin secretory response that ultimately becomes inadequate. The pathogenesis of diabetes mellitus is orchestrated through bidirectional crosstalk between autoimmune aggression and metabolic derangement. γδ T cells, innate-like lymphocytes bridging innate and adaptive immunity, play pivotal roles in tissue homeostasis, inflammation, and immunity through cytokine production and cytotoxicity. This review comprehensively examines the dual roles of γδ T cells across diabetes mellitus types. Furthermore, γδ T cells contribute to diabetic complications and are profoundly affected by the diabetic milieu, leading to defective anti-infection and anti-tumor immunity. We discuss emerging therapeutic strategies targeting γδ T cells or their effector pathways and highlight key knowledge gaps regarding subset-specific functions, dynamic changes during disease progression, and tissue-resident γδ T cell roles. Elucidating these mechanisms may provide a strong foundation for developing novel γδ T cell-based immunotherapies for diabetes mellitus and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.